On May 18, 2018 The Janssen Pharmaceutical Companies of Johnson & Johnson reported a post-hoc analysis from the Phase 3 SPARTAN study that showed treatment with ERLEADA (apalutamide) significantly reduced the risk of prostate specific antigen (PSA) progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who had a rapidly rising PSA while receiving continuous androgen deprivation therapy (ADT) (Abstract PD10-11) (Press release, Johnson & Johnson, MAY 18, 2018, View Source [SID1234526908]). These data were presented during the Prostate Cancer: Advanced (including Drug Therapy) I Oral Podium Session at the 2018 American Urological Association (AUA) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Janssen presented another study that assessed the association between PSA doubling time and both metastasis-free survival (MFS) and overall survival (OS) in patients with nmCRPC (Abstract PD10-04). Shorter PSA doubling time has been associated with shorter time to metastasis or death.1,2

"Patients with non-metastatic castration-resistant prostate cancer are at risk for metastases and mortality. In these patients, PSA doubling time is an important predictor of outcomes, including time to developing metastases or symptoms from their cancer," said Eric Small, M.D. FASCO, Professor of Medicine, Chief of the Division of Hematology and Oncology, and Deputy Director of the Helen Diller Comprehensive Cancer Center at the University of California, San Francisco, and co-principal investigator of the SPARTAN study. "This analysis further underscores the efficacy of apalutamide therapy and helps us understand how PSA changes in these patients are associated with clinical outcomes."

Key Findings from the SPARTAN Study

According to the data from the SPARTAN study presented at AUA 2018, ERLEADA significantly decreased the risk of PSA progression by 94 percent, compared with the placebo group (median not reached vs. 3.71 months; HR=0.06; 95% CI, 0.05-0.08; P<0.0001).3

Additionally, the median time to PSA response was 29 days in the ERLEADA plus ADT group1,2 At 12 weeks after randomization, median PSA decreased by 90 percent in the ERLEADA group and increased by 40 percent in the placebo group.1,2

Among patients treated, baseline median PSA doubling time was 4.4 and 4.5 months, and median baseline PSA was 7.78 and 7.96 ng/mL in the ERLEADA and placebo groups, respectively.3 A ≥90 percent maximum decline in PSA from baseline at any time on study was observed in 66 percent of patients in the ERLEADA group and 1 percent of patients in the placebo group.3

The SPARTAN trial was a Phase 3, randomized, double-blind, placebo-controlled, multicenter study that evaluated ERLEADA in combination with ADT in patients with nmCRPC who had a rapidly rising PSA (PSA doubling time ≤10 months). The primary endpoint was MFS. ERLEADA plus ADT improved MFS by 2 years (24.3 months) compared to placebo plus ADT (40.5 months vs. 16.2 months; HR=0.28; 95% CI, 0.23-0.35; P<0.0001).4

Key Findings from the Population-Based Study

Janssen also presented data from a population-based study designed to evaluate the association of PSA doubling time and baseline PSA levels with MFS and OS in patients with nmCRPC. The study was conducted using an integrated electronic health records and claims database.5 Specifically, PSA doubling time of ≤10 months was associated with shorter MFS and OS and was a marker for high-risk disease.5 Of the patients with evaluable PSA doubling time, 38.2 percent were defined as high-risk and 61.8 percent as low-risk, with a median MFS of 15.2 and 30.5 months, (P<0.0001) and median OS of 36.0 and 57.6 months (P=0.0092), respectively.5

"The data presented today demonstrated that a shorter PSA doubling time can result in poor outcomes for patients, supporting the benefit of ERLEADA in reducing the risk of PSA progression in patients with non-metastatic castration-resistant prostate cancer," said Marco Gottardis, Ph.D., Vice President and Prostate Cancer Disease Area Stronghold Leader for the Oncology Therapeutic Area at Janssen Research & Development, LLC. "Janssen is fully committed to the discovery and development of next-generation treatments and bringing forward data that may help physicians consider treatment options for patients with rapidly rising PSA levels who are at high-risk for metastasis."

Additionally, Janssen will present a moderated poster titled, "Patient Reported Outcomes (PROs) in SPARTAN, a Phase 3, double-blind, randomized study of apalutamide plus androgen deprivation therapy (ADT) vs. placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC)" on Sunday, May 20, from 7:00 a.m. to 9:00 a.m. PST (Abstract MP52-20).6

About Non-Metastatic Castration-Resistant Prostate Cancer

Non-metastatic castration-resistant prostate cancer refers to a disease state in which the cancer no longer responds to medical or surgical treatments that lower testosterone, but has not yet been discovered in other parts of the body using a total body bone scan or CT scan.7 Features include: lack of detectable metastatic disease;7 rapidly rising prostate specific antigen while on androgen deprivation therapy (ADT); and serum testosterone level below 50 ng/dL.8,9 Ninety percent of patients with nmCRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.10 The relative 5-year survival rate for patients with distant stage prostate cancer is 30 percent.11 It is critical to delay the onset of metastasis in patients with nmCRPC.

About ERLEADA

ERLEADA (apalutamide) is an androgen receptor (AR) inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and was approved by the FDA on February 14, 2018 as the first approved treatment for this disease state.4 Apalutamide is the only therapy with a category 1 recommendation for non-metastatic (M0) CRPC in the NCCN Guidelines for Prostate Cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer include apalutamide as a treatment option for patients with non-metastatic (M0) CRPC with a category 1 recommendation (especially for those with a PSA doubling time ≤10 months)*.12 Additionally, the AUA Guidelines for Castration-Resistant Prostate Cancer (CRPC) were recently updated to include apalutamide (ERLEADA) with continued androgen deprivation as a treatment option that clinicians should offer to patients with nmCRPC who are at high-risk for developing metastatic disease (Standard; Evidence Level Grade A)**.13

*Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Standard: Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on Grade A or B evidence.

**Evidence Level: A designation indicating the certainty of the results as high, moderate, or low (A, B, or C, respectively) based on AUA nomenclature and methodology.

INDICATION

ERLEADA (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

ERLEADA IMPORTANT SAFETY INFORMATION4

CONTRAINDICATIONS

Pregnancy — ERLEADA (apalutamide) can cause fetal harm and potential loss of pregnancy.

WARNINGS AND PRECAUTIONS

Falls and Fractures — In a randomized study (SPARTAN), falls and fractures occurred in 16% and 12% of patients treated with ERLEADA compared to 9% and 7% treated with placebo, respectively. Falls were not associated with loss of consciousness or seizure. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone targeted agents.

Seizure — In a randomized study (SPARTAN), 2 patients (0.2%) treated with ERLEADA experienced a seizure. Permanently discontinue ERLEADA in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLEADA. Advise patients of the risk of developing a seizure while receiving ERLEADA and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others.

ADVERSE REACTIONS

Adverse Reactions — The most common adverse reactions (≥10%) were fatigue, hypertension, rash, diarrhea, nausea, weight decreased, arthralgia, fall, hot flush, decreased appetite, fracture, and peripheral edema.

Laboratory Abnormalities — All Grades (Grade 3-4)

Hematology — anemia ERLEADA 70% (0.4%), placebo 64% (0.5%); leukopenia ERLEADA 47% (0.3%), placebo 29% (0%); lymphopenia ERLEADA 41% (2%), placebo 21% (2%)
Chemistry — hypercholesterolemia ERLEADA 76% (0.1%), placebo 46% (0%); hyperglycemia ERLEADA 70% (2%), placebo 59% (1%); hypertriglyceridemia ERLEADA 67% (2%), placebo 49% (0.8%); hyperkalemia ERLEADA 32% (2%), placebo 22% (0.5%)
Rash — Rash was most commonly described as macular or maculo-papular. Adverse reactions were 24% with ERLEADA versus 6% with placebo. Grade 3 rashes (defined as covering > 30% body surface area [BSA]) were reported with ERLEADA treatment (5%) versus placebo (0.3%).

The onset of rash occurred at a median of 82 days. Rash resolved in 81% of patients within a median of 60 days (range: 2 to 709 days) from onset of rash. Four percent of patients treated with

ERLEADA received systemic corticosteroids. Rash recurred in approximately half of patients who were re-challenged with ERLEADA.

Hypothyroidism was reported for 8% of patients treated with ERLEADA and 2% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA and 7% of patients treated with placebo. The median onset was day 113. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted.

DRUG INTERACTIONS

Effect of Other Drugs on ERLEADA — Co-administration of a strong CYP2C8 or CYP3A4 inhibitor is predicted to increase the steady-state exposure of the active moieties. No initial dose adjustment is necessary; however, reduce the ERLEADA dose based on tolerability [see Dosage and Administration (2.2)].

Effect of ERLEADA on Other Drugs — ERLEADA is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of ERLEADA with medications that are primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of ERLEADA with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of UGT must be co-administered with ERLEADA and evaluate for loss of activity.

P-gp, BCRP or OATP1B1 substrates — Apalutamide is a weak inducer of P-glycoprotein (P- gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Concomitant use of ERLEADA with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP or OATP1B1 must be co-administered with ERLEADA and evaluate for loss of activity if medication is continued.